B. Lessard

T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers

R. Kaul, M. Ostrowski, C. Kovacs, 2011, AIDS research and therapy.

Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

J. Singer, V. Martel-Laferrière, C. Tremblay, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Switch From Enfuvirtide to Raltegravir in Patients With Undetectable Viral Load: Efficacy and Safety at 24 Weeks in a Montreal Cohort

Réjean Thomas, R. Lalonde, N. Machouf, 2009, Journal of acquired immune deficiency syndromes.

Circulating (1→3)-β-D-Glucan is associated with immune activation during HIV infection.

V. Martel-Laferrière, C. Tremblay, C. Chartrand-Lefebvre, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Argon plasma coagulation treatment of anal high‐grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2‐year prospective pilot study

D. Rouleau, J. Macleod, F. Coutlée, 2018, HIV medicine.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

C. Tremblay, B. Brenner, D. Rouleau, 2018, Retrovirology.

The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV

A. Burchell, H. Trottier, D. Rouleau, 2017, The Journal of infectious diseases.

Acceptability of anal cancer screening tests for women living with HIV in the EVVA study.

A. Burchell, F. Coutlée, V. Marcus, 2020, Current oncology.

Switch From Enfuvirtide to Raltegravir in Patients With Undetectable Viral Load: Efficacy and Safety at 24 Weeks in a Montreal Cohort

Réjean Thomas, C. Torti, I. Izzo, 2009, Journal of acquired immune deficiency syndromes.